Biosimulation (Software, Molecular Modeling, PB/PK, PKPD, Trial Design, Toxicity Prediction, In-house, Contract Service) Market 2015 - Global Forecasts to 2020

DUBLIN, August 17, 2015 /PRNewswire/ --

Research and Markets (http://www.researchandmarkets.com/research/8qlf8t/biosimulation) has announced the addition of the "Biosimulation Market by Product (Software, Molecular Modeling, PB/PK, PKPD, Trial Design, Toxicity Prediction, In-house, Contract Service), Application & by End Users - Global Forecast to 2020" report to their offering.

     (Logo: http://photos.prnewswire.com/prnh/20130307/600769 )


The biosimulation market is expected to reach USD 2,107.99 Million by 2020 from USD 1,034.93 Million in 2015, growing at a CAGR of 15.29% between 2015 and 2020.

A strong trend of R&D investments in biotechnology and pharmaceutical industries will majorly drive the growth of the market. Other growth factors include the need to curtail drug discovery & development costs, growth in the biologics and biosimilars markets, the increased use of personalized medicines, technological advancements, and periodic product upgradation. The increased applications of biosimulation in the defense, industrial bioprocessing, nutraceuticals, and agri-food production will provide opportunities for market growth.

This report segments the global biosimulation market by product, application, and end user. The global market product segments are software and services. The software segment is further classified into molecular modeling and simulation software, PBPK modeling and simulation software, PK/PD modeling and simulation software, trail design software, toxicity prediction software, and other software (QSP, visualizing and analytical software). The services segment includes into in-house services and external/contract services. In 2015, the software segment is expected to account for the largest share of the global biosimulation market.

The application segments of this market are drug discovery, drug development, and other applications. The drug development application segment is further classified into preclinical testing and clinical trials. The drug discovery segment is divided into target identification & validation and lead identification & optimization. In 2015, drug development is expected to account for the largest share of the global market.

On the basis of end users, the global biosimulation market report is segmented into academic and government research institutes, pharmaceutical and biotechnology companies, contract research organizations (CROs), regulatory authorities, and other end users. In 2015, the pharmaceutical and biotechnology companies segment is expected to account for the largest share of the global market.

Major players in the global biosimulation market are Certara USA, Inc. (U.S.), Simulation Plus Inc. (U.S.), Dassault Systèmes SA (France), Schrödinger Inc. (U.S.), Advanced Chemistry Development, Inc. (Canada), Chemical Computing Group, Inc. (Canada), Physiomics PLC (U.K.), Entelos Holding Corporation (U.S.), Rhenovia Pharma Ltd. (France), and Genedata AG (Switzerland).

For more information visit http://www.researchandmarkets.com/research/8qlf8t/biosimulation

Media Contact: Laura Wood , +353-1-481-1716, press@researchandmarkets.net

SOURCE Research and Markets